Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Emerging Treatments and Technologies

The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

  1. Matthew C. Riddle, MD1,
  2. Julio Rosenstock, MD2,
  3. John Gerich, MD3 and
  4. on behalf of the Insulin Glargine 4002 Study Investigators*
  1. 1Oregon Health and Science University, Portland, Oregon
  2. 2Dallas Diabetes and Endocrine Center, Dallas, Texas
  3. 3University of Rochester Medical Center, Rochester, New York
  1. Address correspondence and reprint requests to Matthew C. Riddle, MD, Oregon Health and Science University, Section of Diabetes L-345, 3181 S.W. Sam Jackson, Portland, OR 97201. E-mail: riddlem{at}ohsu.edu
Diabetes Care 2003 Nov; 26(11): 3080-3086. https://doi.org/10.2337/diacare.26.11.3080
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1—

    FPG (A) and HbA1c (B) during the study. Values in both figures are means; error bars indicate SE.

  • Figure 2—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2—

    Cumulative number of hypoglycemia events. Events with plasma-referenced glucose (PG) ≤72 mg/dl (4.0 mmol/l) (A) and with PG ≤56 mg/dl (3.1 mmol/l) (B) are depicted.

  • Figure 3—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3—

    Distribution of hypoglycemia by time of day. A: The proportion of patients experiencing at least one episode of hypoglycemia documented with plasma-referenced glucose ≤72 mg/dl (4.0 mmol/l). B: The hourly hypoglycemia rates, expressed as events per patient-year at the same plasma-referenced glucose cutoff.

Tables

  • Figures
  • Table 1—

    Forced weekly insulin titration schedule

    Start with 10 IU/day bedtime basal insulin and adjust weekly
    Mean of self-monitored FPG values from preceding 2 daysIncrease of insulin dosage (IU/day)
    ≥180 mg/dl (10 mmol/l)8
    140–180 mg/dl (7.8–10.0 mmol/l)6
    120–140 mg/dl (6.7–7.8 mmol/l)4
    100–120 mg/dl (5.6–6.7 mmol/l)2
    • The treat-to-target FPG was ≤100 mg/dl. Exceptions to this algorithm were 1) no increase in dosage if plasma-referenced glucose <72 mg/dl was documented at any time in the preceding week, and 2) in addition to no increase, small insulin dose decreases (2–4 IU/day per adjustment) were allowed if severe hypoglycemia (requiring assistance) or plasma-referenced glucose <56 mg/dl were documented in the preceding week.

  • Table 2—

    Baseline characteristics of subjects in the study

    GlargineNPH
    n367389
    Sex (F/M) (%)45/5544/56
    Age (years)55 ± 9.556 ± 8.9
    Duration of diabetes (years)8.4 ± 5.559.0 ± 5.57
    BMI (kg/m2)32.5 ± 4.6432.2 ± 4.80
    FPG (mg/dl [mmol/l])198 (11.0) ± 49 (2.71)194 (10.8) ± 47 (2.61)
    HbA1c (%)8.61 ± 0.98.56 ± 0.9
    Ethnicity (%)
     White8483
     Black1113
     Asian33
     Multiracial11
    Hispanic heritage (%)106
    Prior therapy (%)
     SU + metformin7174
     SU only1110
     Metformin only87
     SU + TZD65
     Metformin + TZD33
     TZD only<1<1
    • Data are means ± SD, unless otherwise noted. SU, sulfonylurea; TZD, thiazolidinedione.

PreviousNext
Back to top
Diabetes Care: 26 (11)

In this Issue

November 2003, 26(11)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Treat-to-Target Trial
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Treat-to-Target Trial
Matthew C. Riddle, Julio Rosenstock, John Gerich
Diabetes Care Nov 2003, 26 (11) 3080-3086; DOI: 10.2337/diacare.26.11.3080

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Treat-to-Target Trial
Matthew C. Riddle, Julio Rosenstock, John Gerich
Diabetes Care Nov 2003, 26 (11) 3080-3086; DOI: 10.2337/diacare.26.11.3080
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • APPENDIX
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
  • Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
  • Diabetes Antibody Standardization Program
Show more Emerging Treatments and Technologies

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.